NCT01927263View on ClinicalTrials.gov

A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2016

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

NI-071

100mg/vial

BIOLOGICAL

Infliximab

100mg/vial

Trial Locations (1)

Unknown

NichiIko Investigational Site, Sendai

Sponsors
All Listed Sponsors
lead

Nichi-Iko Pharmaceutical Co., Ltd.

INDUSTRY

NCT01927263 - A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter